Role of Common Herbs- Curcuma Longa and Emblica Officinalis in Metabolic Disorders: A Narrative Review
Life Sciences-Ayurveda
DOI:
https://doi.org/10.22376/ijlpr.2023.13.2.L18-L26Keywords:
Metabolic disorders, Haridra, Amalaki, Nisha-amalaki, Diabetes Mellitus, PCOSAbstract
In the present era, Metabolic disorder is a challenge to the medical community because of its increasing prevalence and unsatisfactory management. There is no permanent remedy, and the patient has to continue the medicine for a longer life. According to Ayurveda, all metabolic diseases are caused due to Jathragnimandya(improper digestion & metabolism). Hence the correction of Agni is the principle to treat it. Various herbs act as agnivardhak (increase digestive fire or Rasayan (Rejuvenator). Haridra (Curcuma longa) and Amalaki (Emblica Officinalis) are the herbal drugs recommended in Ayurveda literature. Ayurveda practitioners are using these medicines for various metabolic disorders. Hence this review was carried out to discover their utility in metabolic disorders. The aim and objective of this review are to study the role of common herbs available worldwide, which are Haridra (Curcuma longa) and Amalaki (Emblicaofficinalis), in metabolic disorders. The related data were collected from classical texts of Ayurveda, google scholar, and PubMed. A total of 10 articles were considered for review. Out of these, four were animal studies, and six were analytical studies in which the assessment parameters were fasting. From this review, few studies have been conducted on only Haridra as compared to Amalaki on the post-meal blood sugar levels, glycolatedhaemoglobin (HbA1c) levels, oral glucose tolerance test, and complete blood count metabolic disorders. The maximum studies are on Nisha-Amalaki(a combination of Haridra&Amalakialongwith bhavna[trituration process] of Amalakiswarasa[Juice form of Emblicaofficinalis]to Haridra[Curcuma longa]) which is found to be effective in Diabetes mellitus and dyslipidemia, which can be considered as the cavity of previous reviews. Therefore, there is a need to conduct studies on Nisha-amalaki to explore its effect on other common metabolic disorders like PCOD, Hypothyroidism.
References
“Metabolic Disorders: MedlinePlus” [cited Jul 27 2015]. Available from: http://www.nim.nih.gov.
Ramachandran A, Mary S, Yamuna A, Murugesan N, Snehalatha C. High prevalence of diabetes and cardiovascular risk factors associated with urbanization in India. Diabetes Care. 2008 May;31(5):893-8. doi: 10.2337/dc07-1207, PMID 18310309.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53. doi: 10.2337/diacare.27.5.1047, PMID 15111519.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8, PMID 12493255.
Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, et al. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011 Jan;29(1):4-16. doi: 10.1097/HJH.0b013e32834000be, PMID 20881867.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000 Feb 28;160(4):526-34. doi: 10.1001/archinte.160.4.526, PMID 10695693.
GarmendiaMadariaga A, Santos Palacios S, Guillén-Grima F, Galofré JC. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J ClinEndocrinolMetab. 2014 Mar;99(3):923-31. doi: 10.1210/jc.2013-2409, PMID 24423323.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J ClinEndocrinolMetab. 2002 Feb;87(2):489-99. doi: 10.1210/jcem.87.2.8182, PMID 11836274.
Laurberg P, Cerqueira C, Ovesen L, Rasmussen LB, Perrild H, Andersen S, et al. Iodine intake as a determinant of thyroid disorders in populations. Best Pract Res ClinEndocrinolMetab. 2010 Feb;24(1):13-27. doi: 10.1016/j.beem.2009.08.013, PMID 20172467.
Teng W, Shan Z, Teng X, Guan H, Li Y, Teng D, et al. effect of iodine intake on thyroid diseases in China. N Engl J Med. 2006 Jun 29;354(26):2783-93. doi: 10.1056/NEJMoa054022, PMID 16807415.
Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program – Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8-13. doi: 10.2337/dc06-1414, PMID 17192325.
Ford ES, Li C, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care. 2008;31(9):1898-904. doi: 10.2337/dc08-0423, PMID 18591398.
Narayan KM, Boyle JP, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care. 2007;30(6):1562-6. doi: 10.2337/dc06-2544, PMID 17372155.
Easton JF, Stephens CR, Angelova M. Risk factors and prediction of very short term versus short/intermediate term post-stroke mortality: a data mining approach. ComputBiol Med. 2014;54:199-210. doi: 10.1016/j.compbiomed.2014.09.003, PMID 25303114.
Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res. 2017;120:34-42. doi: 10.1016/j.phrs.2017.03.008, PMID 28300617.
Moore JX, Chaudhary N, Akinyemiju T. Peer Reviewed: metabolic Syndrome prevalence by race/ethnicity and sex in the United States, National Health and Nutrition Examination Survey, 1988-2012. Prev Chronic Dis. 2017;14:E24.
Kaur J. A comprehensive review on metabolic syndrome. Cardiol Res Pract. 2014;2014:943162. doi: 10.1155/2014/943162, PMID 24711954.
Higgins PT J., Green S. Cochrane handbook for systematic reviews of interventions. Version 5.10. Chapter 7–16. The cocharane collaboration; 2011.
Derosa G, Maffioli P, Simental-Mendía LE, Bo S, Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;111:394-404. doi: 10.1016/j.phrs.2016.07.004, PMID 27392742.
Thompson SV, Hannon BA, An R, Holscher HD. Effects of isolated soluble fiber supplementation on body weight, glycemia, and insulinemia in adults with overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Am J ClinNutr. 2017;106(6):1514-28. doi: 10.3945/ajcn.117.163246, PMID 29092878.
Rao G, Bhat S, Gurumadhva Rao S, Gopalakrishna Bhat P. Effect of treatment with Nishamalaki Powder on glycaemic Control and Markers of Erythrocyte Oxidative Stress in Diabetic Rats Compared to troglitazone. Int J Pharm Sci Rev Res, 19(2). Mar-Apr 2013;25:127-34.
Gupta M, Mathur K, Yadav K, Sharma P, Tilwani K, et al. Effect of Amla (Emblica officinalis) on various physiological and biochemical parameters of metabolic syndrome. Scholars J Appl Med Sci. 2016;4(2C):469-75.
Kavita MB, Kj M, B P. A CLINICAL STUDY ON THE EFFECT OF AMALAKI (INDIAN GOOSEBERRY) AS A FOOD SUPPLEMENT IN DYSLIPIDEMIA. Int J Res Ayurveda Pharm. Jul-Aug 2016;7(4):59-64. doi: 10.7897/2277-4343.074134.
Jayshree S, Dawane VP, et al. study the efficacy of herbal formulation Niśha-āmalakī in animal model of polycystic ovarian disease syndrome. AncSci Life. 2017;37(2):86-93.
Bedarkar PB, NidhiRampara et al. Antihyperglycemic activity of Nisha-Amalaki-An Ayurvedic formulation of turmeric and Emblicaofficinalis. Eur J Biomed Pharm Sci. 2017;4(9):853-6.
Kumar V et al. Amalakirasayana, a traditional Indian drug enhances cardiac mitochondrial and contractile functions and improves cardiac function in rats with hypertrophy www.nature.com/scienticreports. 2017 Aug 17;7(1):8588.
Shengule S et al. Herb-drug interaction of NishaAmalaki and Curcuminoids with metformin in normal and diabetic condition: A disease system approach Biomedicine & Pharmacotherapy. Vol. 101; May 2018. p. 591-8.
Singh MK, Dwivedi S, Yadav SS, Yadav RS, Khattri S. Anti-diabetic Effect of Emblica-officinalis (Amla) Against Arsenic Induced Metabolic Disorder in Mice. Indian J ClinBiochem. 2020;35(2):179-87. doi: 10.1007/s12291-019-00820-5. PMID 32226249.
Kapoor MP, Suzuki K, Derek T, Ozeki M, Okubo T. Clinical evaluation of EmblicaOfficinalisGatertn (Amla) in healthy human subjects: health benefits and safety results from a randomized, double-blind, crossover placebo-controlled study. ContempClin Trials Commun. 2020 Mar;17:100499. doi: 10.1016/j.conctc.2019.100499, PMID 31890983.
Panda V, Deshmukh A, Singh S, Shah T, Hingorani L. An Ayurvedic formulation of Emblicaofficinalis and Curcuma longa alleviates insulin resistance in diabetic rats: involvement of curcuminoids and Polyphenolics. J Ayurveda Integr Med. 2021 Jul-Sep;12(3):506-13. doi: 10.1016/j.jaim.2021.05.005, PMID 34376352.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr. Aman Chhabra, Dr. Vaishali Kuchewar, Dr. Twinkle Joshi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
